Liv-gamma sn inj. (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 63 | Idiopathic thrombocytopenic purpura | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03164915 (ClinicalTrials.gov) | September 27, 2016 | 22/5/2017 | A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) | A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia | Biological: LIV-GAMMA SN Inj. | SK Plasma Co., Ltd. | NULL | Unknown status | 19 Years | N/A | All | 37 | Phase 3 | Korea, Republic of |